Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization

American Journal of Health-System Pharmacy

Volumn 64, Issue 1, 2007, Pages 77-84

  Sandhoff, Brian G ^a,b   Nies, Leslie K ^c,d   Olson, Kari L ^c,d   Nash, James D ^e   Rasmussen, Jon R ^c,d   Merenich, John A ^d,f  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Clinical Pharmacy Services   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e HUMANA INC   (United States)

^f University of Colorado Health Sciences Center   (United States)

Author keywords

Antilipemic agents; Coronary disease; Disease management; Health maintenance organizations; Patient information; Team

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN; DANAZOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; MEVINOLIN; NEFAZODONE; NICOTINIC ACID; PROTEINASE INHIBITOR; RAMIPRIL; RISPERIDONE; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG; VERAPAMIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOLOGIST; CARDIOVASCULAR RISK; CLINICAL PHARMACY; COMBINATION CHEMOTHERAPY; CONSENSUS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ELECTRONIC MEDICAL RECORD; EVIDENCE BASED MEDICINE; FEMALE; GENERAL PRACTITIONER; HEALTH MAINTENANCE ORGANIZATION; HEALTH SERVICE; HEART INFARCTION; HEART REHABILITATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MALE; NURSE; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK REDUCTION; SMOKING CESSATION; SUSTAINED DRUG RELEASE;

EID: 33947174654     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060022     Document Type: Article

References (26)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-9.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360:7-22.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary artery disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-57.
4. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-9.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97.
6. Chobanian AV, Bakris GL, Black HR et al., for the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003; 42:1206-52.
7. Arauz-Paucho C, Parrott MA, Raskin P, for the American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 26(suppl 1):S80-2.
8. Olson KL, Bungard TJ, Tsuyki RT. Cholesterol risk management: a systematic examination of the gap from evidence to practice. Pharmacotherapy. 2001; 21:807-17.
9. Qureshi AI, Suri MF, Guterman LR et al. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the third National Health and Nutrition Examination Survey. Arch Intern Med. 2001; 161:1621-8.
10. Campbell NC, Ritchie LD, Thain J et al. Secondary prevention programs in coronary heart disease: a randomised trial of nurse-led clinics in primary care. Heart. 1998; 80:447-52.
11. O'Donnell D, Chen N, Piziak VK. Goal attainment and maintenance of serum cholesterol in a pharmacist-coordinated lipid clinic. Am J Health-Syst Pharm. 2001; 58:325-30.
12. Wilson W, Quest DW, Wilson M et al. A cardiovascular risk factor reduction clinic. Can J Cardiol. 1999; 15:887-91.
13. Harris DE, Burgess N, Gipson GW et al. Lipid lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol. 1998; 81:929-33.
14. Schaffer J, Wexler LF. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system-results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. Arch Intern Med. 1995; 155:2330-5.
15. McAlister FA, Lawson FM, Teo KK et al. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ. 2001; 323:957-62.
16. Merenich JA, Lousberg GT, Brennan SH et al. Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). Am J Cardiol. 2000; 85:36A-42A.
17. Sueta CA, Chowdhury M, Boccuzzi SJ et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999; 83:1303-7.
18. Grundy SM, Cleeman JI, Merz CN et al., for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-39.
19. Kris-Ehterton PM, Harris WS, Appel LJ, for the American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002; 106:2747-57. [Erratum, Circulation. 2003; 107:512.]
20. Dujovne CA. Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis." Am J Cardiol. 2002; 89:1411-3.
21. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11:272-6
22. Olson KL, Rasmussen J, Sandhoff BG et al. Lipid management of patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization. Arch Int Med. 2005; 165:49-54.
23. Khan NA, McAlister FA, Campbell NC et al. The 2004 Canadian recommendations for the management of hypertension: part II-therapy. Can J Cardiol. 2004; 20:41-59.
24. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(suppl 1):S1-266.
25. American Diabetes Association. Standards of care for patients with diabetes mellitus. Diabetes Care. 2003; 26(suppl 1):S33-50.
26. Yusuf S, Sleight P, Poque J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342:145-53. [Errata, N Engl J Med. 2000; 342:748, 1376.]